Monogram Technologies, Inc.

Monogram Technologies (now part of Zimmer Biomet as of 2025) develops precision robotic surgical systems and personalized orthopedic implant solutions for joint reconstruction. The company's core platform combines navigated surgical robotics with custom 3D-printed implant technology to enable highly personalized joint replacement procedures. The mBôs robotic system delivers precision bone cuts calibrated to individual patient anatomy, while the mVision registration and tracking technology integrates image-guided surgical navigation. Monogram's proprietary software automates clinical workflows, processes patient imaging data using machine learning algorithms, and optimizes implant positioning and alignment. The company targets the $20 billion orthopedic surgery market, specifically addressing limitations in knee and hip replacement procedures. Published research indicates Monogram's technique achieves approximately seven times greater stability compared to conventional hip replacement methods. The company has conducted clinical validation studies with UCLA and maintains an active SEC-registered securities offering. As a Zimmer Biomet subsidiary, Monogram leverages the parent company's regulatory infrastructure and distribution network. Products remain in development and early clinical validation stages.